Blood and marrow transplant clinical trials network: Progress since the state of the science symposium 2007

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 2, 2014, Pages 149-153

  Ferrara, James L M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Acute lymphocytic leukemia; Acute myeloid leukemia; Biomarkers; Cell therapy; Chronic lymphocytic leukemia; Clinical trials; Clinical trials network; Crohn's disease; Graft versus host disease; Hemaphogocytic lymphohistiocytosis; Hematopoietic cell transplantation; Quality of life; T cell lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; DASATINIB; DEXAMETHASONE; DOXORUBICIN; IMMUNOSUPPRESSIVE AGENT; LENALIDOMIDE; PREDNISONE; RAPAMYCIN; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADENOVIRUS INFECTION; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOTRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CROHN DISEASE; CYTOGENETICS; DISEASE FREE SURVIVAL; EPSTEIN BARR VIRUS INFECTION; EXERCISE; FATIGUE; FLOW CYTOMETRY; FULL INTENSITY CONDITIONING; FUNCTIONAL STATUS; GRAFT RECIPIENT; GRAFT VERSUS LEUKEMIA EFFECT; GUIDED IMAGERY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOPHAGOCYTIC SYNDROME; HIGH RISK PATIENT; HUMAN; IMMUNOCOMPETENCE; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM SURVIVAL; MAINTENANCE THERAPY; MEDICAL SOCIETY; MULTICENTER STUDY (TOPIC); MULTIPLE MYELOMA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; PERIPHERAL T CELL LYMPHOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PUVA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REDUCED INTENSITY CONDITIONING; REGULATORY T LYMPHOCYTE; SALVAGE THERAPY; SELF EVALUATION; STRESS; STRESS MANAGEMENT; STUDY DESIGN; SYMPOSIUM; TUMOR REGRESSION; UNRELATED DONORS;

ACUTE LYMPHOCYTIC LEUKEMIA; ACUTE MYELOID LEUKEMIA; BIOMARKERS; CELL THERAPY; CHRONIC LYMPHOCYTIC LEUKEMIA; CLINICAL TRIALS; CLINICAL TRIALS NETWORK; CROHN'S DISEASE; GRAFT-VERSUS-HOST DISEASE; HEMAPHOGOCYTIC LYMPHOHISTIOCYTOSIS; HEMATOPOIETIC CELL TRANSPLANTATION; QUALITY OF LIFE; T CELL LYMPHOMA;

BONE MARROW TRANSPLANTATION; CLINICAL TRIALS AS TOPIC; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTORY, 21ST CENTURY; HUMANS; MALE; TREATMENT OUTCOME;

EID: 84893150787     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.11.006     Document Type: Editorial

References (37)

1. Beschorner W.E., Suresch D.L., Shinozawa T., et al. Thymic immunopathology after cyclosporine: effect of irradiation and age on medullary involution and recovery. Transplant Proc 1988, 20:1072-1078.
2. Shinozawa T., Beschorner W.E., Hess A.D. The thymus and prolonged administration of cyclosporine. Transplant 1990, 50:106-111.
3. Kansu E., Gooley T., Flowers M.E., et al. Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial. Blood 2001, 98:3868-3870.
4. Beschorner W.E., Hess A.D., Shinn C.A., et al. Transfer of cyclosporine-associated syngeneic graft-versus-host disease by thymocytes. Resemblance to chronic graft-versus-host disease. Transplantation 1988, 45:209-215.
5. Santos G.W., Hess A.D., Vogelsang G.B. Graft-versus-host reactions and disease. Immunol Rev 1985, 88:169-192.
6. Nguyen V.H., Zeiser R., Dasilva D.L., et al. Invivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation. Blood 2007, 109:2649-2656.
7. Syrjala K.L., Donaldson G.W., Davis M.W., et al. Relaxation and imagery and cognitive-behavioral training reduce pain during cancer treatment: a controlled clinical trial. Pain 1995, 63:189-198.
8. Dimeo F., Bertz H., Finke J., et al. An aerobic exercise program for patients with haematological malignancies after bone marrow transplantation. Bone Marrow Transplant 1996, 18:1157-1160.
9. Dimeo F., Fetscher S., Lange W., et al. Effects of aerobic exercise on the physical performance and incidence of treatment-related complications after high-dose chemotherapy. Blood 1997, 90:3390-3394.
10. Dimeo F.C., Stieglitz R.D., Novelli-Fischer U., et al. Effects of physical activity on the fatigue and psychologic status of cancer patients during chemotherapy. Cancer 1999, 85:2273-2277.
11. Hayes S., Davies P.S., Parker T., et al. Quality of life changes following peripheral blood stem cell transplantation and participation in a mixed-type, moderate-intensity, exercise program. Bone Marrow Transplant 2004, 33:553-558.
12. Wilson R.W., Jacobsen P.B., Fields K.K. Pilot study of a home-based aerobic exercise program for sedentary cancer survivors treated with hematopoietic stem cell transplantation. Bone Marrow Transplant 2005, 35:721-727.
13. Carlson L.E., Smith D., Russell J., et al. Individualized exercise program for the treatment of severe fatigue in patients after allogeneic hematopoietic stem-cell transplant: a pilot study. Bone Marrow Transplant 2006, 37:945-954.
14. Pasquini MC. CIBMTR Summary Slides Part 1. 2005;Slides Part1.
15. Dispenzieri A., Rajkumar S.V., Gertz M.A., et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc 2007, 82:323-341.
16. Yanada M., Matsuo K., Emi N., et al. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer 2005, 103:1652-1658.
17. Cornelissen J.J., van Putten W.L., Verdonck L.F., et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?. Blood 2007, 109:3658-3666.
18. Tallman M.S., Dewald G.W., Gandham S., et al. Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission. Blood 2007, 110:409-417.
19. Yanada M., Takeuchi J., Sugiura I., et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. JClin Oncol 2006, 24:460-466.
20. Thomas D.A., Faderl S., Cortes J., et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004, 103:4396-4407.
21. de Labarthe A., Rousselot P., Huguet-Rigal F., et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 2007, 109:1408-1413.
22. Montserrat E. New prognostic markers in CLL. Hematol Am Soc Hematol Educ Progr 2006, 279-284.
23. Sorror M.L., Maris M.B., Sandmaier B.M., et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. JClin Oncol 2005, 23:3819-3829.
24. Rizvi M.A., Evens A.M., Tallman M.S., et al. T-cell non-Hodgkin lymphoma. Blood 2006, 107:1255-1264.
25. Filipovich A.H. Hemophagocytic lymphohistiocytosis and related disorders. Curr Opin Allergy Clin Immunol 2006, 6:410-415.
26. Cooper N., Rao K., Gilmour K., et al. Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis. Blood 2006, 107:1233-1236.
27. Baker K.S., Eapen M., Gross T., et al. Unrelated donor hematopoietic cell transplant (HCT) for hemophagocytic lymphohistiocytosis (HLH). Blood 2006, 108:174.
28. Nash R.A., Bowen J.D., McSweeney P.A., et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 2003, 102:2364-2372.
29. Hough R.E., Snowden J.A., Wulffraat N.M. Haemopoietic stem cell transplantation in autoimmune diseases: a European perspective. Br J Haematol 2005, 128:432-459.
30. Nash R.A., McSweeney P.A., Crofford L.J., et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 2007, 110:1388-1396.
31. Oyama Y., Craig R.M., Traynor A.E., et al. Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. Gastroenterology 2005, 128:552-563.
32. Leung Y., Geddes M., Storek J., et al. Hematopoietic cell transplantation for Crohn's disease: is it time?. World J Gastroenterol 2006, 12:6665-6673.
33. Leen A.M., Myers G.D., Sili U., et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006, 12:1160-1166.
34. Amrolia P.J., Muccioli-Casadei G., Huls H., et al. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood 2006, 108:1797-1808.
35. Solomon S.R., Mielke S., Savani B.N., et al. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 2005, 106:1123-1129.
36. Haque T., Wilkie G.M., Jones M.M., et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007, 110:1123-1131.
37. Leen A.M., Bollard C.M., Mendizabal A.M., et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 2013, 121:5113-5123.